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To date, it is widely accepted that high-risk human papillomavirus
types (HR-HPVs), particularly HPV 16 and 18, are causally
involved in the development of cervical cancer and its precursor
stages (IARC, 1995). An increasing prevalence of HR-HPV DNA
has been found from low-grade to high-grade cervical intraepithelial
neoplasia (CIN) lesions (L￿rincz et al, 1992; Lungu et al, 1995), and
HPV DNA is detectable in nearly all cervical carcinomas worldwide
(Bosch et al, 1995; JMM Walboomers, personal communication).
Semi-quantitative PCR studies have shown that 45—96% of
women with CIN III lesions contained a relatively high amount of
DNA of at least one of the HR-HPV types 16, 18, 31, 33 and 35 in
their cervical scrapings. In contrast, the majority (74—88%) of
women with CIN I lesions displayed low HR-HPV DNA levels in
their cervical scrapings (Cuzick et al, 1992, 1994; Bavin et al,
1993; Flanelly et al, 1995). These data are in favour of the viral
load in cervical scrapings being an important determinant for
severity of the underlying cervical lesion.
However, a study using the Hybrid Capture Assay (HCA), an
HPV DNA detection technique not based on DNA amplification,
has revealed lower amounts of viral DNA in cervical scrapings of
women with CIN III lesions compared to these with CIN I lesions
(Farthing et al, 1994). This was supported by Sun et al (1995),
showing that only 30% of women with relatively high levels of HPV
DNA in their cervical scrapings had underlying high-grade CIN.
The discrepancies between the dif ferent studies are likely to be
due to the different methodologies used. Although all the methods
used had in common a semi-quantitative approach, only in the
PCR studies was a correction for the amount of input DNA made.
Since it is conceivable that the number of cells varies considerably
between cervical scrapings, it is likely that the HPV copy number
values calculated from the HCA studies do not always reflect the
actual viral load per genome equivalent. On the other hand, the
semi-quantitative HPV PCR studies described thus far did not
correct for eventual differences in amplification efficiency
between different samples. This may be an additional factor
affecting the outcome of studies on HPV DNA load.
Quantitation of housekeeping genes, most commonly b-globin
or HLA genes, has been used successfully to correct for differences
in input DNA between samples (Kellog et al, 1990). Moreover, to
compensate for fluctuations in amplification efficiency between
samples, exogenous DNA fragments have been incorporated in
competitive PCR assays (Becker-Andr￿ and Hahlbrock, 1989;
Gilliland et al, 1990; Bouaboula et al, 1992; Mulder et al, 1994;
Mallet et al, 1995). The exogenous DNA fragments (referred to as
internal constructs) were often modified versions of the target DNA
to ensure an equal amplification efficiency.
The technical limitations of previous studies on HPV DNA load
prompted us in this study to develop a quantitative (Q-) PCR assay
for accurate measurements of viral DNA load in cervical scrap-
ings. Using an HPV general primer GP5+/6+-mediated PCR
protocol (de Roda Husman et al, 1995) a competitive PCR assay
based on the co-amplification of native HPV 16 target and its
internal construct was developed. Similarly, a competitive b-
globin gene PCR was developed. Following detection of PCR
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products by an enzyme immunoassay (EIA) (Jacobs et al, 1996,
1997), the ratio between outcomes of competitive HPV 16 and b-
globin PCR was then used to determine the amount of HPV 16
DNA per genome equivalent. We demonstrated that co-amplifica-
tion of internal construct and endogenous DNA of both targets was
truly competitive and that this approach allowed for an accurate
quantification of HPV 16 DNA on a per cell basis. Comparative
analyses of this method and semi-quantitative PCR protocols on a
series of HPV 16 containing cervical scrapings learned that correc-
tion for both amount/integrity of input DNA and differences in
amplification efficiency may influence the outcome of studies on
HPV DNA load. Consequently, in order to reconsider putative
associations between viral load and clinical parameters this Q-
PCR approach can be a potentially valuable tool.
MATERIALS AND METHODS
HPV 16 clone, human placental DNA, cell lines and
clinical specimens
The pHPV 16 clone containing full-length HPV 16 DNA was kindly
provided by H Zur Hausen and L Gissmann (Heidelberg, Germany).
Human placental DNA was purchased from Sigma (USA).
The HPV 16 containing human cervical cancer cell lines SiHa
and CaSki were obtained from the American Type Tissue Culture
Collection.
For application of the Q-PCR assay, a total of 48 cytomorpho-
logically abnormal cervical scrapings were used from women who
had visited in the past the outpatients clinic of the University
Hospital Vrije Universiteit in Amsterdam, The Netherlands. All 48
cervical scrapings contained only HPV 16 DNA as previously
determined by HPV type-specific PCRs. The cervical scrapings
were collected in 1 ml 10 mM Tris—HCl, pH 7.5 and prepared for
PCR purposes as described earlier (van den Brule et al, 1990).
Generation of internal constructs for HPV 16 and
b-globin
Internal constructs were generated by site-directed mutagenesis
with overlap extension using PCR as has been previously
described (R￿ster et al, 1995). The primer sequences used are
shown in Table 1. Briefly, for b-globin primer combinations
BGPCO3/BGPCO9 and BGPCO8/BGPCO10 and, for HPV 16,
primer combinations GP16.5/GP8 and GP6+/GP9 were used to
generate two PCR products with an overlapping, rearranged probe
binding sequence at the 5¢ end of the PCR products. The b-globin
and HPV 16 PCR products were amplified from human placental
DNA and pHPV 16 DNA respectively. The two overlapping
PCR products were extended using BGPCO3/BGPCO8 and
GP16.5/GP6+ primers for generating b-globin and HPV 16
constructs respectively. The PCR products were 140 base pairs
for both targets. All PCRs were performed under conditions as
Table 1 Primer and probe sequence
Primer Target Sequence (5¢–3¢)
(bio)BGPCO3 b-globin ACACAACTGTGTTCACTAGC
BGPCO9 b-globin CTTGTGGCCGCAAATCAGCAGGTCTTCCGATGTCTGTTTGAGGTT
BGPCO8 b-globin TTGATACCAACCTGCCCAGG
BGPCO10 b-globin TCGGAAGACCTGCTGATTTGCGGCCACAAGCTGCCGTTACTGCCC
GP16.5 HPV 16 TTTGTTACTGTTGTTGATACTAC
GP8 HPV 16 CAAGACGAAGAATAACGGATGCCTTTTGAATATTTGTACTGCTG
(bio)GP6+ HPV 16 GAAAAATAAACTGTAAATCATATTC
GP9 HPV 16 ATCAAAAGGCATCCGTTATTCTTCGTCTTGAACTACATATAAAAA
GP5+ HPV 16 TTTGTTACTGTGGTAGATACTAC
Probes
WTBGPRO Endogenous b-globin ACTTCTCCTCAGGAGTCAGGTGCACCATGG
ICBGPRO b-globin internal construct CTTGTGGCCGCAAATCAGCAGGTCTTCCGA
WTHPV16PRO Endogenous HPV 16 GTCATTATGTGCTGCCATATCTACTTCAGA
ICHPV16PRO HPV 16 internal construct ATCAAAGGCATCCGTTATTCTTCGTCTTG
Underlined sequences represent the rearranged 30 base pairs probe binding sequence.
Table 2 Accuracy of quantification by Q-PCR-EIA
Mean copy number of HPV 16 per cell
No. of cells (total 105 Expected (min–max)a Calculated (mean ± s.d.)b
HPV 16 copies)*
200 CaSki + 0 SiHa 400–600 395 ± 168.5
195 CaSki + 500 SiHa 113–175.5 94 ± 26.6
150 CaSki + 5000 SiHa 12.6–27.2 11.5 ± 1.2
0 CaSki + 20 000 SiHa 1–10 3.6 ± 0.7
aBased on the assumption that 1 SiHa cell contains 1–10 copies of HPV 16 and 1 CaSki cell contains
400–600 copies of HPV 16 (Caballero et al, 1995). bThe determined values are averages of 3 independent
experiments.116 MV Jacobs et al
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described for HPV type-specific PCR assays (van den Brule et al,
1990). Subsequently, the final PCR products were purified from a
1% agarose gel using a QIAEX II Gel Extraction kit (Qiagen,
Germany) and cloned into a pCRScript Amp SK(+) vector
(Stratagene, USA) following the instructions of the manufacturers￿
protocols. The cloned DNA fragments were then sequenced on a
373A automatic sequencer using dye terminators (Applied
Biosystems, USA) to determine the cloned sequence.
Subsequently, the concentration of the plasmids containing the
cloned sequences was determined by spectrophotometric reading.
Both clones were stored at —80°C until further use.
Competitive PCR using internal constructs
For  b-globin DNA, competitive PCRs were carried out in a
total volume of 50 ml containing 50 mM potassium chloride (KCl),
10 mM Tris—HCl pH 8.3, 200 mM of each dNTP, 1.5 mM magne-
sium chloride (MgCl2), 1 unit of Amplitaq DNA polymerase
(Perkin-Elmer, Emmeryville, USA), 25 pmol of BGPCO3 and
BGPCO8 primers, 10 ml of a sample and 10 ml of the b-globin
internal construct of known concentration. The PCR cycling
conditions were similar as referred to above.
Competitive PCRs for HPV 16 were performed with PCR
mixtures consisting of 50 mM KCl, 10 mM Tris—HCl pH 8.3,
200 mM of each dNTP, 3.5 mM MgCl2, 1 unit of Amplitaq DNA
polymerase (Perkin-Elmer, Emmeryville, USA), 25 pmol of the
general primers GP5+ (Table 1) and GP6+, 10 ml of the sample and
10 ml of the HPV 16 internal construct of known concentration.
PCR amplification was performed under low stringency condi-
tions as described elsewhere (de Roda Husman et al, 1995).
To enable detection of the co-amplified PCR-products in EIA,
BGPCO3 and GP6+ were biotinylated (bioBGPCO3 and bioGP6+
respectively) at their 5¢ end during synthesis (Eurogentec, Luik,
Belgium). Samples were run in triplicate reactions, each spiked
with a different concentration of the internal construct. From
preliminary experiments it was learned that, in general, samples
could be spiked with concentrations varying from 103 to 105 for
HPV 16, and 104 to 106 for b-globin PCR. If the optical density
(OD) ratio fell outside the 2-log range, new triplicate reactions
were performed which were spiked with adjusted amounts of
internal construct to ensure that OD ratios within a 2-log range
were obtained. As positive controls, each internal construct dilu-
tion was amplified alone, while negative controls consisted of
PCR mixtures without sample or construct added.
EIA for the detection of PCR products
The PCR products were analysed in EIA as have been described
previously (Jacobs et al, 1996, 1997). Briefly, biotinylated PCR
products were captured on streptavidin-coated microtitre plates,
denatured by alkaline treatment and hybridized to digoxigenin-
11-ddUTP-labelled oligoprobes (Eurogentec, Luik, Belgium).
Subsequent addition of anti-digoxigenin antibodies conjugated to
alkaline phosphatase and p-nitrophenylphosphate as substrate
finally enabled the detection of the ultimate hybrids by OD reading.
The digoxigenin-labelled oligoprobes used are shown in Table 1.
Quantitation of HPV 16 DNA load by Q-PCR-EIA
After competitive PCR, the amplification products were analysed
in EIA, and the ODs generated by the internal constructs and the
endogenous targets were measured for each individual reaction.
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Assumed that one cell contains two copies of the b-globin gene the
amount of HPV 16 DNA per genome equivalent was calculated
according to the following formula: [(OD targetHPV 16/OD
constructHPV 16) ´ copies constructHPV 16]:[(OD targetb-globin/OD
constructb-globin) ´ copies constructb-globin)/2]. This formula was used
provided that OD ratios fell within a 2-log range.
Semi-quantitative, non-competitive PCR using external
standards
For HPV 16 quantification by semi-quantitative, non-competitive
PCR, aliquots of serial tenfold dilutions of pHPV 16 DNA ranging
from 100 ag to 100 pg were amplified by GP5+/6+ PCR in parallel
experiments with 10 ml of the crude cervical cell suspensions. PCR
amplifications were carried out as described by de Roda Husman
et al (1995).
Following amplification, a standard curve was generated by
plotting the optical densities of the PCR products amplified from
the dilutions of pHPV 16 DNA against the input amount of these
amplified standards. To determine the initial amount of HPV 16
DNA in a given sample, the HPV copy numbers were deduced
from the generated standard curve (Jacobs et al, 1996).
In addition, sample preparation, preparation of PCR solutions,
spiking of the internal constructs and amplification/analysis of
the PCR products were performed in four physically separated
rooms under strict laboratory discipline to avoid contamination.
Moreover, Q-PCR reactions were carried out with the same
primer-, internal construct- and probe batches, whereas analysis of
the different PCR products of each sample was performed in the
same EIA microtitre plate to minimize inter-assay variation.
Statistical analysis
Direct comparison of the results obtained by the different (semi)-
quantitative HPV PCR methods is not possible due to the use
of different measurement units in which viral load is expressed
(fg ml—1 vs fg cells—1). Therefore, statistical analysis was based
on ranking of values. The Spearman rank correlation coefficient
(rs) was calculated to assess the change in association between
samples measured by different (semi-)quantitative HPV PCR
methods. A P-value < 0.05 indicates that the difference between
the two correlation coefficients is significant (Snedecor and
Cochran, 1980).
RESULTS
Assay strategy and generation of internal constructs
In order to develop a quantitative test that accurately assess
the viral load in cervical scrapings, we used the strategy of
two competitive PCRs for quantification of HPV 16 DNA and b-
globin DNA respectively. The ratio of the outcomes of the compet-
itive PCRs for HPV 16 and b-globin DNA enables a calculation of
the HPV 16 DNA load per genome equivalent. For the competitive
HPV PCR, the general primer GP5+/6+-mediated PCR system (de
Roda Husman et al, 1995) was chosen since it allows for the detec-
tion of all major HPV types (HPV 16, 18, 45, 51, 52, 58 and 59)
which are considered currently carcinogenic for humans on the
basis of case—control studies (Chichareon et al, 1997; Ngelangel
et al, 1997). However, since HPV 16 is most commonly found in
cervical carcinomas (Bosch et al, 1995), we first focused on the
development of a competitive PCR for this HPV type.
The internal constructs for this approach were made by site-
directed mutagenesis. These constructs represent HPV 16 and b-
globin gene sequences, including the binding sites for GP5+/6+
and PCO3/PCO8 primer combinations respectively. Although they
give rise to PCR products of the same size as the native targets, the
constructs differ in sequence from the targets by a rearranged
intervening 30 bp sequence (Figure 1). Following PCR, these
rearranged sequences enables distinguising PCR products derived
from the internal constructs from those of the target sequences by
specific oligo probes targeting this region.
Competition of amplification between endogenous
templates and internal constructs in PCR
A reliable competitive PCR assay requires the internal constructs
to be co-amplified with the same efficiency as the target DNA.
Therefore, it was first tested whether competition of amplification
between targets and corresponding internal constructs is indeed
equal. For this purpose, serial tenfold dilutions of target DNA, in
which the amount of endogenous template ranged from 1 to 108
copies, were spiked with serial tenfold dilutions (108 to 1 copies)
of the internal constructs into opposite directions. After competi-
tive PCRs, the amplification products were analysed by gel elec-
trophoresis, followed by Southern blot hybridization (Jacobs et al,
1996), and by EIA respectively. As shown in Figure 2A for HPV
12 34 5
A
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D
E
Figure 2 Competitive PCR results of endogenous HPV 16 target and HPV
16 internal construct. Lane 1: 10 pg pHPV 16 DNA + 102 copies of internal
construct; lane 2: 1 pg pHPV 16 DNA + 103 copies of internal construct; lane
3: 100 fg pHPV 16 DNA + 104 copies of internal construct; lane 4: 10 fg pHPV
16 DNA + 104 copies of internal construct; lane 5: 1 fg pHPV 16 DNA + 105
copies of internal construct. PCR products are shown after gel analysis (A),
and additional Southern blot hybridization of the PCR products with either a
specific oligoprobe for HPV 16 endogenous template (B) or HPV 16 internal
construct (C). PCR products were also differentiated in EIA using oligoprobes
for the target template (D) and internal construct (E) respectively118 MV Jacobs et al
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16, agarose gel analysis revealed PCR products of the same size
derived from both target and internal construct. Moreover, equal
input amounts of target and internal construct resulted in PCR
products with the same signal intensities after Southern blot
hybridization (Figure 2B,C) and equal OD values in EIA (Figure
2D,E) after hybridization with target versus construct probes. This
suggests a true competitive feature of the assay. Thus, when the
amounts of PCR products derived from target and internal
construct are the same, this indicates that quantities of target DNA
are identical to those of spiked construct.
To investigate to what extent quantification is possible when the
amount of initial internal construct differs from target, the HPV 16
target/construct OD ratio values calculated from the competitive
PCR-EIA experiment described in Figure 2D and 2E were
expressed as function of the input amounts of internal construct.
As shown in Figure 3, the curve obtained showed a linear decrease
of target/construct OD ratio with increasing concentration of
internal construct within the range of 0.1—10. Since within this 2-
log range the slope of the curve was very close to 21, this indi-
cates indeed that both target and construct were amplified with
equal efficiencies. Similar results were obtained from competitive
b-globin gene PCR assays (Figure 3). The fact that linearity was
only evident when the OD ratios ranged from 0.1 to 10 indicates
that a reliable quantification requires that the amount of spiked
construct does not differ more than 2-log from the amount of target
DNA. In practice, this requires samples to be spiked with several
amounts of internal construct in parallel experiments to meet this
criterion.
Detection limit and accuracy of Q-PCR-EIA
In order to find out to what level the competitive approach influences
the sensitivity of detecting target DNA, serial tenfold dilutions of
SiHa DNA containing approximately 1—10 HPV 16 copies per cell
and human placental DNA were spiked with different amounts of
HPV 16 and b-globin internal constructs, respectively, and subjected
to Q-PCR-EIA. It appeared that the detection limit of HPV 16
Figure 3 Analysis of HPV 16 and b-globin PCR-EIA. The ratio of optical
densities (ODs) from endogenous template to internal construct (ODET/ODIC)
is plotted on a log-scale against the concentration of the internal construct.
The median values and standard deviations are shown. (——) HPV 16, slope
P = –1.08 in the range of log values between –1 and +1; (- - - -) b-globin,
slope P = –0.89 in the range of log values between –1 and +1
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Figure 4 Comparison of the relative viral load between samples obtained
with quantitative PCR-EIA and two semi-quantitative approaches. Each
column on the x-axis represents an individual sample. Samples are ordered
according to increasing viral load values as calculated with the fully
quantitative Q-PCR-EIA. (A) Competitive GP5+/6+ PCR combined with
competitive b-globin PCR (Q-PCR-EIA); (B) competitive GP5+/6+ PCR
without correction for b-globin quantities; (C) semi-quantitative non-
competitive GP5+/6+ PCRQuantitative HPV PCR-EIA 119
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Q-PCR-EIA was around 1 ng SiHa DNA which corresponds to
103—104 copies of HPV 16 DNA. For b-globin Q-PCR-EIA the
detection limit was around 1 ng of human placental DNA corre-
sponding to around 400 copies of the b-globin gene. This indicates
that by combining the two competitive PCR assays, quantification is
possible provided that at least 103—104 copies of HPV 16 and 400
copies of b-globin gene are present in the sample.
Subsequently, the accuracy of quantification by Q-PCR-EIA
was tested on four mixtures of cells from the cervical cancer
cell lines SiHa and CaSki (containing approximately 500 HPV 16
copies per cell). For this purpose, different amounts of SiHa and
CaSki cells were mixed in such a way that the samples contained a
total of about 105 copies of the HPV 16 DNA. However, the mean
HPV 16 copy number per cell varied considerably between the
different mixtures from approximately 500 to 5 copies per cell. As
shown in Table 2, the number of HPV 16 copies per genome
equivalent as measured with Q-PCR-EIA approximated the
expected mean HPV 16 copy number per cell for all four dilutions
analysed. It should be noted that the standard deviation decreased
with increasing number of cells used for the PCR, suggesting that
the reproducibility of the assay increased with increasing number
of cells present in the assay.
Comparison between quantitative PCR and semi-
quantitative PCR assays on cervical scrapings
Finally, Q-PCR-EIA was applied to 48 HPV 16 containing cervical
scrapings and the outcome was compared with two less stringent
PCR approaches, i.e. a semi-quantitative non-competitive PCR-
EIA (Jacobs et al, 1996, 1997) and the competitive GP5+/6+ PCR-
EIA for HPV 16 without correction for housekeeping gene (i.e.
b-globin gene) quantities. Relative quantities of HPV 16 DNA load
calculated by the three methods are shown in Figure 4.
Comparison of the amounts of HPV 16 copy numbers calcu-
lated by the competitive HPV GP5+/6+ PCR combined with
competitive b-globin PCR and the competitive HPV GP5+/6+
PCR only (Figure 4A vs 4B) using the Spearman rank correlation
test revealed a correlation coefficient (rs) of 0.63 (95% confidence
interval (CI) 0.42—0.78). Comparison of the HPV 16 DNA loads
measured by the competitive HPV GP5+/6+ PCR and the semi-
quantitative non-competitive GP5+/6+ PCR (Figure 4B vs 4C)
yielded a rs of 0.67 (95% Cl 0.47—0.80). The difference between
the two rs values was not significant (P = 0.638). These results
indicate clear differences in the assessment of the viral load in
cervical scrapings depending on the particular method used.
DISCUSSION
Several studies have shown that the number of HPV DNA copies
in cervical scrapings may be predictive for the severity of under-
lying CIN lesion (Cuzick et al, 1992, 1994; Bavin et al, 1993;
Flanelly et al, 1995). In addition, it has also been shown that high
HPV DNA load in cervical scrapings is associated with persistent
CIN (Ho et al, 1995). Hence, HPV DNA load in cervical scrapings
may be a valuable marker, not only for the severity of underlying
cervical lesions but also for the prediction of persistent CIN.
Therefore, methods allowing accurate quantification of viral DNA
in cervical scrapings could be of value to distinguish high-grade
and/or persistent CIN.
In this study we developed a quantitative HPV PCR assay (Q-
PCR-EIA) which corrects both for intertube variations in PCR
efficiency and for variability in the amount of input DNA. This
assay would therefore be useful to quantitate HPV DNA in crude
suspensions of cervical scrapings. Ultimately, viral levels could be
expressed as copy numbers per genome equivalent by calculating
HPV 16/b-globin PCR-EIA OD ratios obtained after co-amplifica-
tion of target DNA and an exogenously added internal construct.
The results demonstrated that this Q-PCR-EIA approach provides
a reliable indication of the viral load in cervical scrapings.
Important for a reliable quantification by competitive PCR
assays is a similar amplification efficiency between target DNA
and competitor (Ferre, 1992). To increase the likelihood that both
endogenous and exogenous templates will be amplified with equal
efficiencies, internal constructs were designed in such a way that
primer binding sequences, sizes and base composition were
similar compared to the target sequences. Application of these
constructs in competitive PCR assays revealed an equal amplifica-
tion efficiency as long as the target/construct OD ratio fell within a
2-log range. Such a dynamic range is comparable to that of other
competitive PCR assays developed for a variety of micro-
organisms (Kellog et al, 1990; Bouaboula et al, 1992; Mallet et al,
1995; R￿ster, Zeuzem and Hahlbrock, 1995; Rowe et al, 1997).
The HPV 16 Q-PCR-EIA was validated in reconstruction exper-
iments using mixtures of two different cervical carcinoma cell
lines (CaSki and SiHa) with known HPV 16 copy number per cell.
The experiments revealed a good agreement between expected and
calculated mean viral copy numbers per genome. The lack of exact
agreement may be due to slight variations in the exact HPV 16
copy numbers in CaSki and/or SiHa cells, or, alternatively aneu-
ploidy of the cancer cells. The latter may result in an altered mean
copy number of the b-globin gene per cell. Moreover, it has to be
noted that the reproducibility (standard deviation) of the quantita-
tive method was markedly lower for the dilutions containing only
200 cancer cells. This is most likely due to the limit of quantifica-
tion by the competitive b-globin PCR which was found to be at the
level of 400 copies of the b-globin gene, equivalent to 200 diploid
cells. However, it is more conceivable that in practice the
threshold of the competitive HPV 16 PCR (103—104) is the limiting
factor for the quantitative approach since cervical scrapings
contain on average 105—106 exfoliated cells (L￿rincz, 1996).
The comparison of different (semi-)quantitative HPV PCR
assays on a series of HPV 16 positive cervical scrapings revealed
that two major factors affect the outcome of studies on quantitative
HPV DNA load. First, the observed difference between competi-
tive HPV GP5+/6+ PCR and a combined competitive HPV/b-
globin PCR indicates the existence of variations in the number of
cells present in cervical scrapings and/or integrity of DNA.
Second, an additional difference in relative viral load was evident
after comparison of competitive GP5+/6+ PCR and the semi-
quantitative non-competitive GP5+/6+ PCR. The latter points to
intertube variations in PCR efficiency. Apparently, cervical scrap-
ings differ considerably with respect to the eventual presence and
amount of PCR interfering factors. Since the calculated rs values
did not differ significantly, it can be concluded that both intertube
variations in PCR efficiency and variations in amounts/integrity of
input DNA equally affect quantitative measurements of HPV
DNA in cervical scrapings.
Previously, Kinoshita et al (1993) have described a competitive
HPV 16 PCR based on primer sequences from the E6 region.
However, their approach did not include a correction for the
amount of input DNA. Therefore, this method is only applicable to
constant input amounts of isolated DNA, rather than crude cell120 MV Jacobs et al
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suspensions. Still, even this approach is hampered by the fact that
no corrections are made for eventual variations in integrity of the
DNA between different DNA samples. Another, more simple
approach has been described by Caballero et al (1995). Their
method has been based on differences in signal intensities between
HPV-specific and co-amplified non-specific DNA of higher
molecular weight, generated in a low-stringency PCR system using
HPV general primers GP5/6. In this assay, the amplified non-
specific products serve as controls for both PCR efficiency and
amounts/integrity of input DNA. A major advantage of this method
is that only a single PCR reaction is necessary to meet all criteria to
be fulfilled for reliable quantification. However promising, this
method is subject to limitations as well. In our hands, efficiency of
HPV 16 DNA amplification was not proportional to the amplifica-
tion efficiency of the non-specific fragment in dilution experiments
(data not shown), particularly when the levels of HPV target were
relatively high. This suggests a non-equal competition between
amplification of both targets, which may partly be due to the fact
that the non-specific fragment is larger in size. Moreover, the non-
specific target of unknown origin may not match as good with the
PCR primers as the HPV target. This also has the consequence that
minor variations in stringency, due to differences between crude
cell suspensions, may have a more drastic affect on the efficiency of
amplifying non-specific target than HPV target. Therefore, we feel
that this method is more sensitive to subtle variations in PCR condi-
tions, which may particularly be the case when using crude cervical
samples rather than isolated DNA. In contrast, the Q-PCR-EIA
described in this study is completely independent from slight differ-
ences in PCR conditions and would be the method of choice for
crude cell suspensions. Since this method is based on the general
primer format, it potentially can be converted to Q-PCR assays for
other HPV types. Of course, such a conversion requires first addi-
tional reconstruction experiments to test the efficiency of competi-
tion before application in practice.
Finally, this Q-PCR-EIA system provides a valuable tool to
reconsider putative associations between viral load and clinical
parameters. In this context, we are currently investigating HPV 16
DNA load in a non-intervention follow-up study of women with
abnormal cytology (Remmink et al, 1995). The outcome of such
studies ultimately will clarify whether or not viral load has any
predictive value for persistent viral infections and/or severity of
underlying CIN lesions.
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